尾加压素Ⅱ在肾癌患者血液和孵育组织中的表达

Expression of urotensin Ⅱ in human renal clear cell carcinoma

目的测定肾癌患者和正常对照人群血液和孵育组织中尾加压素Ⅱ(Urotensin Ⅱ,UⅡ)的表达量,以期探讨UⅡ表达在肾透明细胞癌发生中的临床意义。方法对20例肾透明细胞癌患者及20例对照人群通过放免方法检测血液和孵育组织UII的表达。结果肾癌患者和正常对照人群血液和孵育组织中均有UⅡ表达。放免结果显示肾透明细胞癌组患者血浆UII水平(50.08±4.77 pg/ml)与正常对照组血浆UⅡ(45.55±6.05 pg/ml)相比差异无统计学意义(P>0.05)。肾透明细胞癌组织孵育后UII水平(30.83±8.51 pg/mg pro)明显高于正常肾组织(16.09±3.13 pg/mgpro)(P<0.01)。结论肾透明细胞癌组织可分泌UⅡ,且较正常肾组织高,提示UⅡ可能与肾透明细胞癌的发生、发展有关,UⅡ可能通过自分泌或旁分泌的方式发挥作用。

Objective To investigate the expression of urotensin II （UII） in plasma and secreted UII content from carcinoma tissues in patients with renal clear cell carcinoma in order to assess a possible autocrine/paracrine role of UII in renal tumors. Methods According to the diagnostic and excluding criteria, the patients with renal clear cell carcinoma and normal persons were recruited, plasma UII levels and secreted UII contents were measured by radioimmunoassay. Results There was no significant difference in plasma UII levels between the control and renal clear cell carcinoma patients groups （45.55 ＋ 6.05 pg/ml vs 50.08 ＋ 4.77 pg/ml, respectively, P 〉 0.05 ）. UII content secreted from carcinoma tis- sues was higher than normal renal tissues （30.83 ± 8.51 pg/mg pro vs 16.09 ± 3.13 pg/mg pro, respectively, P 〈 0.01 ）. Conclusion UII may act as a growth stimulating factor in renal clear cell carcinoma in an autocrine/paracrine manner.